(Q39461271)

12 September 2017

Brompheniramine, terfenadine, and placebo in allergic rhinitis (English)

1 reference

12 September 2017

1 reference

Klein GL

1

1 reference

12 September 2017

Littlejohn T 3rd

series ordinal

2

1 reference

12 September 2017

Lockhart EA

series ordinal

3

1 reference

12 September 2017

Furey SA

series ordinal

4

1 reference

12 September 2017

1 November 1996

1 reference

Annals of Allergy, Asthma & Immunology

12 September 2017

1 reference

12 September 2017

77

1 reference

12 September 2017

5

1 reference

12 September 2017

365-370

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963334-0

12 September 2017

1 reference

7 January 2021

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963334-0

1 reference

7 January 2021

H1-receptor antagonists. Comparative tolerability and safety

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963334-0

7 January 2021

Further use of color coding in drug evaluations; parabromdylamine in perennial allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963334-0

7 January 2021

Parabromdylamine maleate, chlorprophenpyridamine maleate, and tripelennamine hydrochloride in chronic allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963334-0

7 January 2021

Terfenadine. An updated review of its pharmacological properties and therapeutic efficacy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963334-0

7 January 2021

Controlled trial of terfenadine and chlorpheniramine maleate in perennial rhinitis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2963334-0

7 January 2021

10.1016/S1081-1206(10)63334-0

Identifiers

DOI

1 reference

12 September 2017

1 reference